Glycopyronium and Formoterol Fumarate
Sponsors
Astrazeneca AB, AstraZeneca AB
Conditions
Severe and inadequately controlled asthma
Phase 3
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pressurised MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS)
CompletedCTIS2023-505787-11-00
Start: 2021-04-29End: 2025-03-18Target: 678Updated: 2025-05-05
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)
CompletedCTIS2023-505786-88-00
Start: 2021-04-25End: 2025-03-19Target: 441Updated: 2025-03-21